4D Molecular Therapeutics (FDMT) Return on Sales (2020 - 2025)
Historic Return on Sales for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 631.72%.
- 4D Molecular Therapeutics' Return on Sales rose 139822800.0% to 631.72% in Q3 2025 from the same period last year, while for Sep 2025 it was 1742.84%, marking a year-over-year increase of 66932200.0%. This contributed to the annual value of 4345.7% for FY2024, which is 43408500.0% down from last year.
- Per 4D Molecular Therapeutics' latest filing, its Return on Sales stood at 631.72% for Q3 2025, which was up 139822800.0% from 3639.8% recorded in Q2 2025.
- 4D Molecular Therapeutics' Return on Sales' 5-year high stood at 1698.53% during Q4 2023, with a 5-year trough of 49650.0% in Q4 2024.
- Over the past 5 years, 4D Molecular Therapeutics' median Return on Sales value was 123.95% (recorded in 2023), while the average stood at 4168.06%.
- Per our database at Business Quant, 4D Molecular Therapeutics' Return on Sales tumbled by -513485300bps in 2024 and then skyrocketed by 139822800bps in 2025.
- 4D Molecular Therapeutics' Return on Sales (Quarter) stood at 272.57% in 2021, then soared by 92bps to 21.96% in 2022, then surged by 7835bps to 1698.53% in 2023, then plummeted by -3023bps to 49650.0% in 2024, then soared by 99bps to 631.72% in 2025.
- Its last three reported values are 631.72% in Q3 2025, 3639.8% for Q2 2025, and 3431.36% during Q1 2025.